Clinigen extends distribution deal with healthcare firm Accord

BURTON upon Trent pharmaceuticals firm Clinigen Group has extended its exclusive clinical trial distribution agreement with Accord Healthcare for another two years.

The European agreement adds four new products across additional therapeutic areas, taking the total up to 17

The agreement has also been extended to include the solid dose oncology drug temozolomide and Accord’s first biosimilar, Accofil (filgrastim) for the treatment of chemotherapy-induced neutropenia (an abnormally low number of neutrophil white blood cells).

And for the first time, the agreement has been expanded to include drugs from additional therapeutic areas including diabetes (glimepiride) and transplant rejection (mycophenelate).

Clinigen has partnered with Accord since 2012 to deliver its oncology products, including cisplatin, cytarabine, docetaxel, doxorubicin and fluorouracil, into clinical trials.

Daniel Green, regional director UK & Ireland at Accord said: “We have been impressed with the service provided by Clinigen CTS since 2012 and are pleased to be able to continue and extend our exclusive agreement with an additional four new products.”

New director appointed at Britvic

SOFT drinks group Britvic – which has operations in Solihull and Tamworth – has announced the appointment of Mathew Dunn, chief financial officer, as a director of the company with immediate effect.
 
Dunn joined the business in September and, following a period of overlap to ensure a smooth transition, he succeeded John Gibney as chief financial officer on the announcement of the firm’s preliminary results.

Gibney will remain on the board until the company’s AGM on January 27 and will remain with the company until his retirement in April.

Severn Trent making “good progress”

COVENTRY-based utility Severn Trent has reported a good start to its new regulatory period.

Announcing its interim results for the six months to September 30, it said profit before tax was up 2.6% to £281m while group turnover was flat at £896.1m.

The firm said it is making good progress in all operational metrics with 83% showing improvements.

Chief executive Liv Garfield said: “I am pleased to report strong progress in the first half of the year, marking a good start to the new regulatory period.  As we continue to become an even more customer-focused business we have delivered some great improvements, evidenced by the decline in customer complaints, and we continue to have the lowest combined bills in Britain.
 
“We are committed to delivering continued outperformance for the benefit of our customers, colleagues and shareholders, having already delivered tangible results in the first half.”